Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Common Equity: 2020-2024

Historic Common Equity for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $1.0 billion.

  • Janux Therapeutics' Common Equity rose 48.84% to $976.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $976.6 million, marking a year-over-year increase of 48.84%. This contributed to the annual value of $1.0 billion for FY2024, which is 197.02% up from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' Common Equity is $1.0 billion, which was up 197.02% from $344.3 million recorded in FY2023.
  • Janux Therapeutics' Common Equity's 5-year high stood at $1.0 billion during FY2024, with a 5-year trough of -$14.6 million in FY2020.
  • Over the past 3 years, Janux Therapeutics' median Common Equity value was $344.3 million (recorded in 2023), while the average stood at $562.6 million.
  • Per our database at Business Quant, Janux Therapeutics' Common Equity skyrocketed by 2,602.58% in 2021 and then decreased by 12.44% in 2022.
  • Yearly analysis of 5 years shows Janux Therapeutics' Common Equity stood at -$14.6 million in 2020, then skyrocketed by 2,602.58% to $366.3 million in 2021, then decreased by 12.44% to $320.7 million in 2022, then increased by 7.36% to $344.3 million in 2023, then spiked by 197.02% to $1.0 billion in 2024.